ENTRY       D10778            Mixture   Drug
NAME        Elbasvir and grazoprevir;
            Zepatier (TN)
PRODUCT     ZEPATIER (Merck Sharp & Dohme LLC)
COMPONENT   Elbasvir [DR:D10625], (Grazoprevir hydrate [DR:D10639] | Grazoprevir [DR:D11565])
CLASS       Antiviral
             DG03198  Anti-HCV agent
REMARK      ATC code: J05AP54
            Product: D10778<US>
EFFICACY    Antiviral
  DISEASE   Chronic hepatitis C [DS:H00413]
COMMENT     treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection
TARGET      HCV NS3/4A protease [KO:K22273 K22274]
            HCV NS5A [KO:K22275]
  PATHWAY   ko03230(K22273+K22274+K22275)  Viral genome structure
            ko03240(K22273+K22274+K22275)  Viral replication
            ko05160(K22273+K22274+K22275)  Hepatitis C
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AP Antivirals for treatment of HCV infections
                 J05AP54 Elbasvir and grazoprevir
                  D10778  Elbasvir and grazoprevir &lt;US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-hepatitis C (HCV) Agents
               Elbasvir/ Grazoprevir
                D10778  Elbasvir and grazoprevir
            Drug groups [BR:br08330]
             Antiviral
              DG03198  Anti-HCV agent
               D10778  Elbasvir and grazoprevir
            Drug classes [BR:br08332]
             Antiviral
              DG03198  Anti-HCV agent
               D10778  Elbasvir and grazoprevir
            Antimicrobials [BR:br08307]
             Antivirals
              Polyprotein cleavage inhibitor
               HCV NS3/4A inhibitor
                D10778  Elbasvir and grazoprevir &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10778
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10778
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10778
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D10778
DBLINKS     PubChem: 313046636
            ChEBI: 132973
///
